Global Cord Blood Stock Price, News & Analysis (NYSE:CO)

Global Cord Blood trades on the New York Stock Exchange (NYSE) under the ticker symbol "CO."

Global Cord Blood Corp (NYSE:CO) issued its quarterly earnings results on Tuesday, August, 27th. The medical research company reported $0.13 earnings per share (EPS) for the quarter. The medical research company earned $39.82 million during the quarter. Global Cord Blood had a net margin of 31.78% and a return on equity of 9.60%. View Global Cord Blood's Earnings History.

Global Cord Blood is scheduled to release their next quarterly earnings announcement on Tuesday, November 26th 2019. View Earnings Estimates for Global Cord Blood.

Press coverage about CO stock has trended very negative this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Global Cord Blood earned a media sentiment score of -3.9 on InfoTrie's scale. They also gave media coverage about the medical research company a news buzz of 3.0 out of 10, meaning that recent press coverage is unlikely to have an effect on the company's share price in the near future. View News Stories for Global Cord Blood.

Global Cord Blood saw a decrease in short interest in the month of September. As of September 30th, there was short interest totalling 44,100 shares, a decrease of 86.8% from the August 30th total of 334,600 shares. Based on an average daily trading volume, of 108,200 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.1% of the company's stock are sold short. View Global Cord Blood's Current Options Chain.

Some companies that are related to Global Cord Blood include Verra Mobility (VRRM), Bain Capital Specialty Finance (BCSF), GS ACQUISITION /SH CL A (GSAH), HAYMAKER ACQUIS/SH CL A (HYAC), Trinity Merger (TMCX), Repay (RPAY), THUNDER BRDG AC/SH SH (TBRG), Pivotal Acquisition (PVT), FORUM MERGER II/SH CL A (FMCI), Opes Acquisition (OPES), ANDINA ACQUISIT/SH SH (ANDA), AgroFresh Solutions (AGFS), Allied Esports Entertainment (AESE), KBL MERGER CORP/SH (KBLM) and Pensare Acquisition (WRLS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Global Cord Blood investors own include NovaBay Pharmaceuticals (NBY), Galectin Therapeutics (GALT), Micron Technology (MU), AEterna Zentaris (AEZS), Arotech (ARTX), Exelixis (EXEL), Eyepoint Pharmaceuticals (EYPT), Fate Therapeutics (FATE), Immunomedics (IMMU) and Madrigal Pharmaceuticals (MDGL).

Global Cord Blood's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Campbell & CO Investment Adviser LLC (0.01%). View Institutional Ownership Trends for Global Cord Blood.

CO stock was bought by a variety of institutional investors in the last quarter, including Campbell & CO Investment Adviser LLC. View Insider Buying and Selling for Global Cord Blood.

Shares of CO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CO stock can currently be purchased for approximately $5.67.

Global Cord Blood has a market capitalization of $689.19 million and generates $147.03 million in revenue each year. Global Cord Blood employs 1,261 workers across the globe.View Additional Information About Global Cord Blood.

The official website for Global Cord Blood is http://www.globalcordbloodcorp.com/.

Global Cord Blood's mailing address is 48 FL. BANK OF CHINA TOWER 1 GARDEN ROAD, HONG KONG K3, . The medical research company can be reached via phone at 852-3605-8180 or via email at [email protected]